Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$27.0M
Filings
138
Firms Hired
2
Active Period
2006–2024
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Accelerating Kids’ Access to Care Act
2024 · first_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes H.R.5237, The Reduced Cost and Continued Cures Act SMART Prices Act (S. 1264) Lowering Drug Costs for American Families Act (H.R. 4895) Executive Order on Strengthening Access to Affordable, High Quality Contraception & Family Planning Services Accelerating Kids Access to Care Act (S. 2372, H.R. 4758) The Modernizing and Ensuring PBM Accountability Act (no bill # yet) Medicaid Drug Rebate Proposed Rule
Client expense: $210,000 · Firm income: —
Matched citations: H.R. 4758
Lowering Drug Costs for American Families Act
2024 · first_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes H.R.5237, The Reduced Cost and Continued Cures Act SMART Prices Act (S. 1264) Lowering Drug Costs for American Families Act (H.R. 4895) Executive Order on Strengthening Access to Affordable, High Quality Contraception & Family Planning Services Accelerating Kids Access to Care Act (S. 2372, H.R. 4758) The Modernizing and Ensuring PBM Accountability Act (no bill # yet) Medicaid Drug Rebate Proposed Rule
Client expense: $210,000 · Firm income: —
Matched citations: H.R. 4895
Fentanyl Crisis Research and Evaluation Act
2024 · first_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes H.R.5237, The Reduced Cost and Continued Cures Act SMART Prices Act (S. 1264) Lowering Drug Costs for American Families Act (H.R. 4895) Executive Order on Strengthening Access to Affordable, High Quality Contraception & Family Planning Services Accelerating Kids Access to Care Act (S. 2372, H.R. 4758) The Modernizing and Ensuring PBM Accountability Act (no bill # yet) Medicaid Drug Rebate Proposed Rule
Client expense: $210,000 · Firm income: —
Matched citations: H.R.5237
SMART Prices Act
2024 · first_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes H.R.5237, The Reduced Cost and Continued Cures Act SMART Prices Act (S. 1264) Lowering Drug Costs for American Families Act (H.R. 4895) Executive Order on Strengthening Access to Affordable, High Quality Contraception & Family Planning Services Accelerating Kids Access to Care Act (S. 2372, H.R. 4758) The Modernizing and Ensuring PBM Accountability Act (no bill # yet) Medicaid Drug Rebate Proposed Rule
Client expense: $210,000 · Firm income: —
Matched citations: S. 1264
Accelerating Kids’ Access to Care Act
2024 · first_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes H.R.5237, The Reduced Cost and Continued Cures Act SMART Prices Act (S. 1264) Lowering Drug Costs for American Families Act (H.R. 4895) Executive Order on Strengthening Access to Affordable, High Quality Contraception & Family Planning Services Accelerating Kids Access to Care Act (S. 2372, H.R. 4758) The Modernizing and Ensuring PBM Accountability Act (no bill # yet) Medicaid Drug Rebate Proposed Rule
Client expense: $210,000 · Firm income: —
Matched citations: S. 2372
Accelerating Kids’ Access to Care Act
2023 · fourth_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes H.R.5237, The Reduced Cost and Continued Cures Act SMART Prices Act (S. 1264) Lowering Drug Costs for American Families Act (H.R. 4895) Executive Order on Strengthening Access to Affordable, High Quality Contraception & Family Planning Services Accelerating Kids Access to Care Act (S. 2372, H.R. 4758) The Modernizing and Ensuring PBM Accountability Act (no bill # yet) Medicaid Drug Rebate Proposed Rule
Client expense: $340,000 · Firm income: —
Matched citations: H.R. 4758
Lowering Drug Costs for American Families Act
2023 · fourth_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes H.R.5237, The Reduced Cost and Continued Cures Act SMART Prices Act (S. 1264) Lowering Drug Costs for American Families Act (H.R. 4895) Executive Order on Strengthening Access to Affordable, High Quality Contraception & Family Planning Services Accelerating Kids Access to Care Act (S. 2372, H.R. 4758) The Modernizing and Ensuring PBM Accountability Act (no bill # yet) Medicaid Drug Rebate Proposed Rule
Client expense: $340,000 · Firm income: —
Matched citations: H.R. 4895
Fentanyl Crisis Research and Evaluation Act
2023 · fourth_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes H.R.5237, The Reduced Cost and Continued Cures Act SMART Prices Act (S. 1264) Lowering Drug Costs for American Families Act (H.R. 4895) Executive Order on Strengthening Access to Affordable, High Quality Contraception & Family Planning Services Accelerating Kids Access to Care Act (S. 2372, H.R. 4758) The Modernizing and Ensuring PBM Accountability Act (no bill # yet) Medicaid Drug Rebate Proposed Rule
Client expense: $340,000 · Firm income: —
Matched citations: H.R.5237
SMART Prices Act
2023 · fourth_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes H.R.5237, The Reduced Cost and Continued Cures Act SMART Prices Act (S. 1264) Lowering Drug Costs for American Families Act (H.R. 4895) Executive Order on Strengthening Access to Affordable, High Quality Contraception & Family Planning Services Accelerating Kids Access to Care Act (S. 2372, H.R. 4758) The Modernizing and Ensuring PBM Accountability Act (no bill # yet) Medicaid Drug Rebate Proposed Rule
Client expense: $340,000 · Firm income: —
Matched citations: S. 1264
Accelerating Kids’ Access to Care Act
2023 · fourth_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes H.R.5237, The Reduced Cost and Continued Cures Act SMART Prices Act (S. 1264) Lowering Drug Costs for American Families Act (H.R. 4895) Executive Order on Strengthening Access to Affordable, High Quality Contraception & Family Planning Services Accelerating Kids Access to Care Act (S. 2372, H.R. 4758) The Modernizing and Ensuring PBM Accountability Act (no bill # yet) Medicaid Drug Rebate Proposed Rule
Client expense: $340,000 · Firm income: —
Matched citations: S. 2372
Steel Industry Preservation Act
2023 · third_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes H.R.5237, The Reduced Cost and Continued Cures Act S.3427, The Neuroscience Center of Excellence Act of 2021 FDA Neurology Drug Program SMART Prices Act (S. 1264) Lowering Drug Costs for American Families Act (H.R. 4895) Executive Order on Strengthening Access to Affordable, High Quality Contraception & Family Planning Services Accelerating Kids Access to Care Act (S. 2372, H.R. 4758) The Modernizing and Ensuring PBM Accountability Act (no bill # yet) Medicaid Drug Rebate Proposed Rule
Client expense: $210,000 · Firm income: —
Matched citations: H.R. 4758
SUPPORT Act of 2021
2023 · third_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes H.R.5237, The Reduced Cost and Continued Cures Act S.3427, The Neuroscience Center of Excellence Act of 2021 FDA Neurology Drug Program SMART Prices Act (S. 1264) Lowering Drug Costs for American Families Act (H.R. 4895) Executive Order on Strengthening Access to Affordable, High Quality Contraception & Family Planning Services Accelerating Kids Access to Care Act (S. 2372, H.R. 4758) The Modernizing and Ensuring PBM Accountability Act (no bill # yet) Medicaid Drug Rebate Proposed Rule
Client expense: $210,000 · Firm income: —
Matched citations: H.R. 4895
Reduced Costs and Continued Cures Act of 2021
2023 · third_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes H.R.5237, The Reduced Cost and Continued Cures Act S.3427, The Neuroscience Center of Excellence Act of 2021 FDA Neurology Drug Program SMART Prices Act (S. 1264) Lowering Drug Costs for American Families Act (H.R. 4895) Executive Order on Strengthening Access to Affordable, High Quality Contraception & Family Planning Services Accelerating Kids Access to Care Act (S. 2372, H.R. 4758) The Modernizing and Ensuring PBM Accountability Act (no bill # yet) Medicaid Drug Rebate Proposed Rule
Client expense: $210,000 · Firm income: —
Matched citations: H.R.5237
Resiliency for Ranching and Natural Conservation Health Act
2023 · third_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes H.R.5237, The Reduced Cost and Continued Cures Act S.3427, The Neuroscience Center of Excellence Act of 2021 FDA Neurology Drug Program SMART Prices Act (S. 1264) Lowering Drug Costs for American Families Act (H.R. 4895) Executive Order on Strengthening Access to Affordable, High Quality Contraception & Family Planning Services Accelerating Kids Access to Care Act (S. 2372, H.R. 4758) The Modernizing and Ensuring PBM Accountability Act (no bill # yet) Medicaid Drug Rebate Proposed Rule
Client expense: $210,000 · Firm income: —
Matched citations: S. 1264
Recovering America’s Wildlife Act of 2022
2023 · third_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes H.R.5237, The Reduced Cost and Continued Cures Act S.3427, The Neuroscience Center of Excellence Act of 2021 FDA Neurology Drug Program SMART Prices Act (S. 1264) Lowering Drug Costs for American Families Act (H.R. 4895) Executive Order on Strengthening Access to Affordable, High Quality Contraception & Family Planning Services Accelerating Kids Access to Care Act (S. 2372, H.R. 4758) The Modernizing and Ensuring PBM Accountability Act (no bill # yet) Medicaid Drug Rebate Proposed Rule
Client expense: $210,000 · Firm income: —
Matched citations: S. 2372
Neuroscience Center of Excellence Act of 2021
2023 · third_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes H.R.5237, The Reduced Cost and Continued Cures Act S.3427, The Neuroscience Center of Excellence Act of 2021 FDA Neurology Drug Program SMART Prices Act (S. 1264) Lowering Drug Costs for American Families Act (H.R. 4895) Executive Order on Strengthening Access to Affordable, High Quality Contraception & Family Planning Services Accelerating Kids Access to Care Act (S. 2372, H.R. 4758) The Modernizing and Ensuring PBM Accountability Act (no bill # yet) Medicaid Drug Rebate Proposed Rule
Client expense: $210,000 · Firm income: —
Matched citations: S.3427
Reduced Costs and Continued Cures Act of 2021
2023 · second_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes Executive Order on Drug Pricing H.R.5237, The Reduced Cost and Continued Cures Act S.3427, The Neuroscience Center of Excellence Act of 2021 Prescription Drug User Fees FDA Neurology Drug Program H.Res.1390, Expressing support for the protected class
Client expense: $340,000 · Firm income: —
Matched citations: H.R.5237
Expressing support for the protection of Medicare part D's six protected classes.
2023 · second_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes Executive Order on Drug Pricing H.R.5237, The Reduced Cost and Continued Cures Act S.3427, The Neuroscience Center of Excellence Act of 2021 Prescription Drug User Fees FDA Neurology Drug Program H.Res.1390, Expressing support for the protected class
Client expense: $340,000 · Firm income: —
Matched citations: H.Res.1390
Neuroscience Center of Excellence Act of 2021
2023 · second_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes Executive Order on Drug Pricing H.R.5237, The Reduced Cost and Continued Cures Act S.3427, The Neuroscience Center of Excellence Act of 2021 Prescription Drug User Fees FDA Neurology Drug Program H.Res.1390, Expressing support for the protected class
Client expense: $340,000 · Firm income: —
Matched citations: S.3427
Reduced Costs and Continued Cures Act of 2021
2023 · first_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes Executive Order on Drug Pricing H.R.5237, The Reduced Cost and Continued Cures Act S.3427, The Neuroscience Center of Excellence Act of 2021 Prescription Drug User Fees FDA Neurology Drug Program H.Res.1390, Expressing support for the protected class
Client expense: $200,000 · Firm income: —
Matched citations: H.R.5237
Expressing support for the protection of Medicare part D's six protected classes.
2023 · first_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes Executive Order on Drug Pricing H.R.5237, The Reduced Cost and Continued Cures Act S.3427, The Neuroscience Center of Excellence Act of 2021 Prescription Drug User Fees FDA Neurology Drug Program H.Res.1390, Expressing support for the protected class
Client expense: $200,000 · Firm income: —
Matched citations: H.Res.1390
Neuroscience Center of Excellence Act of 2021
2023 · first_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes Executive Order on Drug Pricing H.R.5237, The Reduced Cost and Continued Cures Act S.3427, The Neuroscience Center of Excellence Act of 2021 Prescription Drug User Fees FDA Neurology Drug Program H.Res.1390, Expressing support for the protected class
Client expense: $200,000 · Firm income: —
Matched citations: S.3427
Reduced Costs and Continued Cures Act of 2021
2022 · fourth_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes Executive Order on Drug Pricing S. 2327, Seniors Prescription Drug Relief Act H.R.5237, The Reduced Cost and Continued Cures Act H.R.6000, the CURES 2.0 Act S.3427, The Neuroscience Center of Excellence Act of 2021 Prescription Drug User Fees FDA Neurology Drug Program H.Res.1390, Expressing support for the protected class
Client expense: $360,000 · Firm income: —
Matched citations: H.R.5237
Cures 2.0 Act
2022 · fourth_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes Executive Order on Drug Pricing S. 2327, Seniors Prescription Drug Relief Act H.R.5237, The Reduced Cost and Continued Cures Act H.R.6000, the CURES 2.0 Act S.3427, The Neuroscience Center of Excellence Act of 2021 Prescription Drug User Fees FDA Neurology Drug Program H.Res.1390, Expressing support for the protected class
Client expense: $360,000 · Firm income: —
Matched citations: H.R.6000
Expressing support for the protection of Medicare part D's six protected classes.
2022 · fourth_quarter · Firm: SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)
Inflation Reduction Act Medicare Part D 6 Protected Classes Executive Order on Drug Pricing S. 2327, Seniors Prescription Drug Relief Act H.R.5237, The Reduced Cost and Continued Cures Act H.R.6000, the CURES 2.0 Act S.3427, The Neuroscience Center of Excellence Act of 2021 Prescription Drug User Fees FDA Neurology Drug Program H.Res.1390, Expressing support for the protected class
Client expense: $360,000 · Firm income: —
Matched citations: H.Res.1390
Source: Senate LDA